LIN LINDE PLC
Industrial Inorganic Chemicals · Nasdaq · SEC CIK 1707925 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY-1.2%
TTM EPS YoY0.8%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR5.4%
Margins
Gross margin47.9%
Operating margin25.3%
Net margin19.3%
FCF margin14.0%
EBITDA margin35.8%
Returns
ROE18.0%
ROA8.1%
ROIC (approx.)12.5%
Asset turnover0.42x
Leverage & solvency
Liabilities / assets53.5%
Debt / equity0.56x
Current ratio0.86x
Interest coverage35.51x
Cash quality & payout
Operating cash flow / net income1.53x
Accruals ratio-4.3%
Payout ratio41.6%
Capex / revenue15.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $33.99B | $33.01B |
| Cost of revenue | $17.39B | $17.14B |
| Gross profit | $16.60B | $15.86B |
| R&D expense | $147.00M | $150.00M |
| SG&A expense | $3.43B | $3.34B |
| Operating income | $8.92B | $8.63B |
| Interest expense | $255.00M | $256.00M |
| Pretax income | $8.90B | $8.57B |
| Income tax | $1.99B | $2.00B |
| Net income | $6.90B | $6.57B |
| EBITDA | $12.69B | $12.41B |
| EPS (basic) | 14.69 | 13.71 |
| EPS (diluted) | 14.61 | 13.62 |
| Dividends declared per share | 6.00 | 5.56 |
| Weighted avg. shares (diluted) | 472.19M | 482.09M |
| Banking | ||
| Net interest income | -$255.00M | -$256.00M |
| Balance sheet | ||
| Cash & equivalents | $5.06B | $4.85B |
| Receivables | $4.97B | $4.62B |
| Inventory | $2.06B | $1.95B |
| Current assets | $13.32B | $12.95B |
| PP&E, net | $28.26B | $24.77B |
| Goodwill | $27.93B | $25.94B |
| Intangibles | $11.87B | $11.33B |
| Total assets | $86.82B | $80.15B |
| Current liabilities | $15.20B | $14.54B |
| Short-term debt | $1.80B | $2.06B |
| Long-term debt | $20.68B | $15.34B |
| Total debt | $22.48B | $17.40B |
| Total liabilities | $47.08B | $40.66B |
| Shareholders' equity | $38.24B | $38.09B |
| Net debt | $17.42B | $12.55B |
| Cash flow statement | ||
| Operating cash flow | $10.35B | $9.42B |
| Capital expenditure | $5.26B | $4.50B |
| Free cash flow | $5.09B | $4.93B |
| Investing cash flow | -$5.72B | -$4.64B |
| Financing cash flow | -$4.55B | -$4.36B |
| Depreciation & amortization | $3.76B | $3.78B |
| Stock-based compensation | $164.00M | $160.00M |
| Dividends paid | $2.81B | $2.65B |
| Share buybacks | $4.60B | $4.48B |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.